Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 2001-2007

  Sie, A S ^a   Mensenkamp, A R ^a   Adang, E M M ^a   Ligtenberg, M J L ^a   Hoogerbrugge, N ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

colorectal cancer; genetic; hereditary; Lynch syndrome; screening

Indexed keywords

AGED; COLORECTAL TUMOR; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MALE; MIDDLE AGED; MISMATCH REPAIR; PATHOLOGY;

AGED; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; DNA MISMATCH REPAIR; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84930802499     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu361     Document Type: Article

References (31)

1. Jarvinen, H.J., Renkonen-Sinisalo, L., Aktan-Collan, K., et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27 (2009), 4793–4797.
2. Vasen, H.F., Blanco, I., Aktan-Collan, K., et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62 (2013), 812–823.
3. Umar, A., Boland, C.R., Terdiman, J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004), 261–268.
4. Vasen, H.F., Watson, P., Mecklin, J.P., Lynch, H.T., New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116 (1999), 1453–1456.
5. Dekker, N., Hermens, R.P., Nagengast, F.M., et al. Familial colorectal cancer risk assessment needs improvement for more effective cancer prevention in relatives. Colorectal Dis 15 (2013), e175–e185 discussion e185.
6. Lynch, H.T., Lynch, P.M., Lanspa, S.J., et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76 (2009), 1–18.
7. Ligtenberg, M.J., Kuiper, R.P., Chan, T.L., et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41 (2009), 112–117.
8. Boland, C.R., Thibodeau, S.N., Hamilton, S.R., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998), 5248–5257.
9. Manders, P., Spruijt, L., Kets, C.M., et al. Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome. Eur J Cancer 47 (2011), 1407–1413.
10. Kievit, W., de Bruin, J.H., Adang, E.M., et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 54 (2005), 97–102.
11. Balmana, J., Balaguer, F., Cervantes, A., et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol 24:Suppl 6 (2013), vi73–vi80.
12. NCCN Guidelines: Genetic/Familial High-Risk Assessment: Colorectal (Version 2.2013).
13. Moreira, L., Balaguer, F., Lindor, N., et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308 (2012), 1555–1565.
14. Statistics Netherlands, StatLine, 2013 The Hague, The Netherlands.
15. College voor Zorgverzekeringen, Handleiding voor kostenonderzoek, 2010 Diemen, The Netherlands.
16. Raad voor Volksgezondheid en Zorg, Zinnige en duurzame zorg, 2006 Zoetermeer, The Netherlands.
17. Hampel, H., Frankel, W.L., Martin, E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26 (2008), 5783–5788.
18. Hampel, H., Frankel, W.L., Martin, E., et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352 (2005), 1851–1860.
19. van Lier, M.G., Leenen, C.H., Wagner, A., et al. Yield of routine molecular analyses in colorectal cancer patients
20. Julie, C., Tresallet, C., Brouquet, A., et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 103 (2008), 2825–2835 quiz 2836.
21. Comprehensive Cancer Centres, the Netherlands. Amsterdam, The Netherlands: Netherlands Cancer Registry. 2013.
22. Netherlands Foundation for the Detection of Hereditary Tumours (STOET). 2005. Leiden, The Netherlands.
23. Comprehensive Cancer Centres the Netherlands, Oncoline guideline: hereditary colorectal cancer, 2008 Utrecht, The Netherlands.
24. de Vos tot Nederveen Cappel, W.H., Buskens, E., van Duijvendijk, P., et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 52 (2003), 1752–1755.
25. Wagner, A., van Kessel, I., Kriege, M.G., et al. Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer 4 (2005), 295–300.
26. Jarvinen, H.J., Aarnio, M., Mustonen, H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118 (2000), 829–834.
27. Gudgeon, J.M., Belnap, T.W., Williams, J.L., Williams, M.S., Impact of age cutoffs on a lynch syndrome screening program. J Oncol Pract 9 (2013), 175–179.
28. Mvundura, M., Grosse, S.D., Hampel, H., Palomaki, G.E., The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 12 (2010), 93–104.
29. Ladabaum, U., Wang, G., Terdiman, J., et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 155 (2011), 69–79.
30. Syngal, S., Weeks, J.C., Schrag, D., et al. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129 (1998), 787–796.
31. Overbeek, L.I., Ligtenberg, M.J., Willems, R.W., et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 32 (2008), 1246–1251.